Isabelle Broek-Vande

Brasschaat, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Comparative Analysis of Bone Marrow, cfDNA and CTCs for NGS-Based Multiple Myeloma Detection: A Pilot Study Indicating the Potential of CTCs.

Comparative Analysis of Bone Marrow, cfDNA and CTCs for NGS-Based Multiple Myeloma Detection: A Pilot Study Indicating the Potential of CTCs.

Journal: Cancers
Published: November 06, 2025

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.

Journal: Blood advances
Published: March 12, 2025

Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study.

Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study.

Journal: Cancers
Published: September 20, 2022

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.

Journal: Clinical hematology international
Published: August 11, 2022

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.

Journal: HemaSphere
Published: July 06, 2022

Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry study.

Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry study.

Journal: Acta clinica Belgica
Published: September 26, 2019

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma.

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma.

Journal: Cancers
Published: July 26, 2019

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

Journal: Blood cancer journal
Published: August 18, 2016

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Journal: Anticancer research
Published: December 06, 2015

Continuous treatment in multiple myeloma: the future?

Continuous treatment in multiple myeloma: the future?

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Published: October 01, 2013

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Journal: PloS one
Published: July 13, 2013

Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.

Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.

Journal: Annals of medicine
Published: June 18, 2013
Showing 1-12 of 15

Last Updated: 09/26/2026